Titre :

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.

Auteur(s) :

Meyer, Antoine [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Fumery, Mathurin [Auteur]
Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV [PERITOX]
Peyrin-Biroulet, Laurent [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Filippi, Jérôme [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Altwegg, Romain [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Bouhnik, Yoram [Auteur]
Hôpital Beaujon [AP-HP]
Serrero, Melanie [Auteur]
Aix Marseille Université [AMU]
Laharie, David [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Roblin, Xavier [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Abitbol, Vered [Auteur]
Hôpital Cochin [AP-HP]
Cadiot, Guillaume [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Nancey, Stephane [Auteur]
Hospices Civils de Lyon [HCL]
Allez, Matthieu [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Gilletta, Cyrielle [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Vuitton, Lucine [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Savoye, Guillaume [Auteur]
Université de Rouen Normandie [UNIROUEN]
Nahon, Stephane [Auteur]
Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
Bourrier, Anne [Auteur]
CHU Saint-Antoine [AP-HP]
Buisson, Anthony [Auteur]
CHU Estaing [Clermont-Ferrand]
Bouguen, Guillaume [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Bourreille, Arnaud [Auteur]
Institut des Maladies de l'Appareil Digestif
Viennot, Stephanie [Auteur]
CHU Caen
Carbonnel, Frank [Auteur]
Amiot, Aurelien [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]

Titre de la revue :

Scandinavian Journal of Gastroenterology

Nom court de la revue :

Scand J Gastroenterol

Numéro :

57

Pagination :

1-9

Date de publication :

2022-07-19

ISSN :

1502-7708

Mot(s)-clé(s) en anglais :

Ulcerative colitis
ustekinumab
maintenance therapy
effectiveness
safety

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Introduction There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. Methods We retrieved the full datasets of two ...
Lire la suite >Introduction There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. Methods We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events. Propensity scores weighted comparison was applied. Results In total, 121 patients were included in the vedolizumab group and 97 were included in the ustekinumab group. At week 14 and week 52, in the weighted cohort, no difference was found between vedolizumab and ustekinumab for steroid-free clinical remission (OR = 0.55 [0.21–1.41], p = .21 and 0.94 [0.40–2.22], p = .89, respectively). There was no difference between vedolizumab and ustekinumab for secondary outcomes such as clinical remission, hospitalization, UC-related surgery, treatment persistence and serious and infectious adverse events. Conclusion In patients with UC for whom anti-TNF therapy failed, no difference was found between vedolizumab and ustekinumab after propensity scores weighted comparison. Further studies are required to determine predictive factors of the efficacy of both biological agents.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T01:04:40Z
2024-03-18T10:54:18Z